491 related articles for article (PubMed ID: 26606676)
1. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
[TBL] [Abstract][Full Text] [Related]
2. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.
Nogi Y; Nagashima M; Terasaki M; Nohtomi K; Watanabe T; Hirano T
PLoS One; 2012; 7(4):e35683. PubMed ID: 22536426
[TBL] [Abstract][Full Text] [Related]
3. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
Al-Sharea A; Murphy AJ; Huggins LA; Hu Y; Goldberg IJ; Nagareddy PR
Atherosclerosis; 2018 Apr; 271():166-176. PubMed ID: 29518749
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice.
Terasaki M; Hiromura M; Mori Y; Kohashi K; Kushima H; Ohara M; Watanabe T; Andersson O; Hirano T
Int J Endocrinol; 2017; 2017():1365209. PubMed ID: 28408925
[TBL] [Abstract][Full Text] [Related]
6. A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Terasaki M; Yashima H; Mori Y; Saito T; Matsui T; Hiromura M; Kushima H; Osaka N; Ohara M; Fukui T; Hirano T; Yamagishi SI
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32646003
[TBL] [Abstract][Full Text] [Related]
7. Macrophage foam-cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose.
Hayek T; Hussein K; Aviram M; Coleman R; Keidar S; Pavoltzky E; Kaplan M
Atherosclerosis; 2005 Nov; 183(1):25-33. PubMed ID: 16216589
[TBL] [Abstract][Full Text] [Related]
8. IgE Contributes to Atherosclerosis and Obesity by Affecting Macrophage Polarization, Macrophage Protein Network, and Foam Cell Formation.
Zhang X; Li J; Luo S; Wang M; Huang Q; Deng Z; de Febbo C; Daoui A; Liew PX; Sukhova GK; Metso J; Jauhiainen M; Shi GP; Guo J
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):597-610. PubMed ID: 31996021
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
[TBL] [Abstract][Full Text] [Related]
10. CLI-095 decreases atherosclerosis by modulating foam cell formation in apolipoprotein E-deficient mice.
Wang XQ; Wan HQ; Wei XJ; Zhang Y; Qu P
Mol Med Rep; 2016 Jul; 14(1):49-56. PubMed ID: 27176130
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
[TBL] [Abstract][Full Text] [Related]
12. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N
Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828
[TBL] [Abstract][Full Text] [Related]
13. Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice.
Nagashima M; Watanabe T; Shiraishi Y; Morita R; Terasaki M; Arita S; Hongo S; Sato K; Shichiri M; Miyazaki A; Hirano T
Atherosclerosis; 2010 Sep; 212(1):70-7. PubMed ID: 20684826
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
[TBL] [Abstract][Full Text] [Related]
16. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Joubert M; Jagu B; Montaigne D; Marechal X; Tesse A; Ayer A; Dollet L; Le May C; Toumaniantz G; Manrique A; Charpentier F; Staels B; Magré J; Cariou B; Prieur X
Diabetes; 2017 Apr; 66(4):1030-1040. PubMed ID: 28052965
[TBL] [Abstract][Full Text] [Related]
17. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
Hirano T; Mori Y
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):80-6. PubMed ID: 27186361
[TBL] [Abstract][Full Text] [Related]
18. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE
Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z
Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929
[No Abstract] [Full Text] [Related]
19. Proteoglycan 4 regulates macrophage function without altering atherosclerotic lesion formation in a murine bone marrow-specific deletion model.
Nahon JE; Hoekstra M; Havik SR; Van Santbrink PJ; Dallinga-Thie GM; Kuivenhoven JA; Geerling JJ; Van Eck M
Atherosclerosis; 2018 Jul; 274():120-127. PubMed ID: 29772480
[TBL] [Abstract][Full Text] [Related]
20. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
Terasaki M; Nagashima M; Watanabe T; Nohtomi K; Mori Y; Miyazaki A; Hirano T
Metabolism; 2012 Jul; 61(7):974-7. PubMed ID: 22225957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
